FDA's Center for Biologics Evaluation and Research (CBER) regulates biological products for human use under applicable federal laws, including the Public Health Service Act and the Federal Food, Drug and Cosmetic Act. CBER protects and advances the public health by ensuring that biological products are safe and effective and available to those who need them. CBER also provides the public with information to promote the safe and appropriate use of biological products.
CBER’s performance measures reported in the FDA-TRACK Program align to the CBER 2021-2025 Strategic Plan. The CBER Strategic Plan is organized by four goals. Each goal is briefly described below with links to visualizations and dashboards. Explore the progress CBER is making by strategic goal on the FDA-TRACK website.
CBER 2021-2025 Strategic Goals
Facilitate the Development and Availability of Safe and Effective Medical Products Through the Integration of Advances in Science and Technology